![These highlights do not include all the information needed to use ZAVZPRET safely and effectively. See full prescribing information for ZAVZPRET. ZAVZPRET™ (zavegepant) nasal spray Initial U.S. Approval: 2023 These highlights do not include all the information needed to use ZAVZPRET safely and effectively. See full prescribing information for ZAVZPRET. ZAVZPRET™ (zavegepant) nasal spray Initial U.S. Approval: 2023](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=zavzpret-07.jpg&id=713331)
These highlights do not include all the information needed to use ZAVZPRET safely and effectively. See full prescribing information for ZAVZPRET. ZAVZPRET™ (zavegepant) nasal spray Initial U.S. Approval: 2023
![Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial - The Lancet Neurology Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial - The Lancet Neurology](https://www.thelancet.com/cms/attachment/758fba25-445f-4cce-a682-6346499928ba/gr2_lrg.jpg)
Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial - The Lancet Neurology
![These highlights do not include all the information needed to use ZAVZPRET safely and effectively. See full prescribing information for ZAVZPRET. ZAVZPRET™ (zavegepant) nasal spray Initial U.S. Approval: 2023 These highlights do not include all the information needed to use ZAVZPRET safely and effectively. See full prescribing information for ZAVZPRET. ZAVZPRET™ (zavegepant) nasal spray Initial U.S. Approval: 2023](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=zavzpret-10.jpg&id=713331)
These highlights do not include all the information needed to use ZAVZPRET safely and effectively. See full prescribing information for ZAVZPRET. ZAVZPRET™ (zavegepant) nasal spray Initial U.S. Approval: 2023
![Intranasal zavegepant shows promise for acute migraine treatment | Latest news for Doctors, Nurses and Pharmacists | Pharmacy Intranasal zavegepant shows promise for acute migraine treatment | Latest news for Doctors, Nurses and Pharmacists | Pharmacy](https://pubmiddleware.mims.com/resource/image/62C1743B-BD92-4BE6-9E8C-AD180004830B/OriginalThumbnail/THUMBNAIL_shutterstock_627170372.jpg)
Intranasal zavegepant shows promise for acute migraine treatment | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
![Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial - The Lancet Neurology Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial - The Lancet Neurology](https://www.thelancet.com/cms/attachment/4e24bb07-29fd-4218-8637-6b6b53e4f9b5/gr1.gif)
Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial - The Lancet Neurology
![Zavegepant nasal spray receives approval for acute migraine - Hospital Pharmacy EuropeHospital Pharmacy Europe Zavegepant nasal spray receives approval for acute migraine - Hospital Pharmacy EuropeHospital Pharmacy Europe](https://hospitalpharmacyeurope.com/wp-content/uploads/2023/03/Zavegepant-nasal-spray-receives-approval-for-acute-migraine.jpg)